Effects of selective thromboxane synthetase inhibitor OKY-046 on plasma prostaglandins in patients with coronary artery disease during exercise.
Shikano
M
M
Ogawa
K
K
Ito
T
T
Chen
L S
LS
Ito
Y
Y
Imaizumi
M
M
Uno
T
T
Tsutsumi
S
S
Satake
T
T
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000179:Acrylates / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008689:Methacrylates / Q000627:therapeutic use*; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D005082:Physical Exertion; D010974:Platelet Aggregation / Q000187:drug effects; D011453:Prostaglandins / Q000097:blood*; D013929:Thromboxane B2 / Q000097:blood; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D000179:Acrylates; D008689:Methacrylates; D011453:Prostaglandins; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D010088:Oxidoreductases; D013930:Thromboxane-A Synthase; C034364:ozagrel